相关实验视频

Updated: Jul 23, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

由移植转移的转移性癌症的自发回归

Mikhail V Kiselevskiy¹, Elena G Gromova², Nikolay A Kozlov³

¹Laboratory of Cell Immunity, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115552, Russia.

Exploration of targeted anti-tumor therapy

|July 17, 2023

概括

一个罕见的通过器官移植传播的癌症病例在免疫抑制撤销后自发回归. 这突出了免疫系统的作用.

科学领域:

在瘤学瘤学.
移植免疫学移植免疫学
医学案例报告病例报告

背景情况:

通过器官移植传播恶性瘤是一种罕见但严重的并发症.
标准管理包括免疫抑制停止和异种移植移除,通常随后是辅助疗法.
移植后的扩散性癌症通常需要除了移植外的积极治疗.

研究的目的:

报告一种具有自发回归的传染性恶性瘤的独特病例.
研究免疫系统识别在消除传染性癌症中的作用.
为了强调免疫抑制退出后免疫媒介瘤排斥的潜力.

主要方法:

一个31岁的女性接受脏移植的案例报告.
诊断多重转移 (MTS) 的传染性恶性瘤.
治疗包括移植切除和停止免疫抑制疗法.

主要成果:

患者经历了移植切除术后转移性癌症的自发回归和免疫抑制的撤销.
供体和受体之间的人类白细胞抗原 (HLA) 的不匹配与瘤识别有关.
免疫系统在识别瘤为异物后,有效地消除了瘤.

结论:

取消免疫抑制疗法可以使宿主免疫系统拒绝传播的恶性瘤.
人类白细胞抗原 (HLA) 不相容性在免疫媒介排斥捐赠者传播的瘤中起着至关重要的作用.
这一案例强调了通过器官移植传播的癌症的免疫监测和排斥的潜力.

关键词:

癌症癌症癌症癌症免疫抑制疗法是一种免疫抑制疗法.脏移植移植脏移植自发回归自发回归自发回归.

更多相关视频

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

相关概念视频

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Kidney Transplant II: Surgical Procedure

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...